• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Mpro inhibitors
Ensitrelvir Matches Ritonavir‑Boosted Nirmatrelvir for Rapid SARS‑CoV‑2 Clearance — PLATCOV Phase 2 Results Support an Alternative Oral Mpro Inhibitor
Posted inInfectious Diseases news

Ensitrelvir Matches Ritonavir‑Boosted Nirmatrelvir for Rapid SARS‑CoV‑2 Clearance — PLATCOV Phase 2 Results Support an Alternative Oral Mpro Inhibitor

Posted by By MedXY 11/23/2025
Phase 2 PLATCOV results show oral ensitrelvir accelerates SARS‑CoV‑2 clearance versus no drug and has antiviral effects close to ritonavir‑boosted nirmatrelvir, supporting further phase 3 evaluation.
Read More
  • Single low‑dose primaquine (0.25 mg/kg) is safe and effective for blocking Plasmodium falciparum transmission in children and adults
  • Human Monoclonal Antibody MAM01 for Malaria Prevention: Phase 1 Trial Insights and Context in Antimalarial Monoclonal Antibody Development
  • 初级保健中健康老龄化的标准集:新核心结果集(COS)的关键建议
  • A Standard Set for Healthy Aging in Primary Care: Key Recommendations from the New Core Outcome Set (COS) Consensus
  • What, When and How to Measure Post COVID-19 Condition: The New Core Outcome Set for Clinical Trials
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials depression diabetes diet epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial screening sleep treatment type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in